EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

The shortcoming of using glibenclamide in exploratory clinical headache provocation studies

Palle Christophersen, Tino Dyhring iD

Cephalalgia · 2023

DOI: 10.1177/03331024231219475 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cephalalgia, 2023. Verfasst von Palle Christophersen und 1 weiteren Autor:innen. Beteiligte Einrichtung: Saniona A/S, Glostrup, Denmark. Hauptthemen laut MEDLINE: Potassium Channels, Inwardly Rectifying, Migraine Disorders. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 12 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objective

Preclinical and clinical studies implicate the vascular ATP-sensitive potassium (K ATP ) channel in the signaling cascades underlying headache and migraine. However, attempts to demonstrate that the K ATP channel inhibitor glibenclamide would attenuate triggered headache in healthy volunteers have proven unsuccessful. It is questionable, however, whether target engagement was achieved in these clinical studies.

Methods

Literature data for human glibenclamide pharmacokinetics, plasma protein binding and functional IC 50 values were used to predict the K ATP receptor occupancy (RO) levels obtained after glibenclamide dosing in the published exploratory clinical headache provocation studies. RO vs. time profiles of glibenclamide were simulated for the pancreatic K ATP channel subtype Kir6.2/SUR1 and the vascular subtype Kir6.1/SUR2B.

Results

At the clinical dose of 10 mg of glibenclamide used in the headache provocation studies, predicted maximal occupancy levels of up to 90% and up to 26% were found for Kir6.2/SUR1 and Kir6.1/SUR2B, respectively.

Conclusions

The findings of the present study indicate that effective Kir6.1/SUR2B target engagement was not achieved in the clinical headache provocation studies using glibenclamide. Therefore, development of novel selective Kir6.1/SUR2B inhibitors, with good bioavailability and low plasma protein binding, is required to reveal the potential of K ATP channel inhibition in the treatment of migraine.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Potassium Channels, Inwardly RectifyingMigraine DisordersHumansGlyburideSulfonylurea ReceptorsHeadacheAdenosine Triphosphate

Stichwörter der Autor:innen

KATPMigrainemodelingreceptor occupancytarget engagement

Substanzen

GlyburideSulfonylurea ReceptorsPotassium Channels, Inwardly RectifyingAdenosine Triphosphate

Autor:innen und Institutionen

  • Saniona A/S, Glostrup, Denmark.

ORCID-Profile: Tino Dyhring

Zitieren

APA

Christophersen, P., & Dyhring, T. (2023). The shortcoming of using glibenclamide in exploratory clinical headache provocation studies. Cephalalgia. https://doi.org/10.1177/03331024231219475

Vancouver

Christophersen P, Dyhring T. The shortcoming of using glibenclamide in exploratory clinical headache provocation studies. Cephalalgia. 2023. doi:10.1177/03331024231219475

BibTeX
@article{Christophersen2023,
  author = {Christophersen, Palle and Dyhring, Tino},
  title = {The shortcoming of using glibenclamide in exploratory clinical headache provocation studies},
  journal = {Cephalalgia},
  year = {2023},
  doi = {10.1177/03331024231219475}
}
Kostenlos starten →